Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: A prospective study

European Journal of Cancer Care

Volumn 21, Issue 4, 2012, Pages 485-492

  Biglia, N ^a   Bounous, V E ^a   Malabaila, A ^a   Palmisano, D ^a   Torta, D M E ^a   D'Alonzo, M ^a   Sismondi, P ^a   Torta, R ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Breast cancer; Chemotherapy; Cognitive dysfunction; Neuropsychological assessment

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; COGNITION; COGNITIVE DEFECT; DRUG EFFECT; FEMALE; HUMAN; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PROSPECTIVE STUDY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COGNITION; COGNITION DISORDERS; FEMALE; HUMANS; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PROSPECTIVE STUDIES;

EID: 84862248244     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/j.1365-2354.2011.01320.x     Document Type: Article

References (43)

1. Ahles T.A. & Saykin A.J. (2007) Candidate mechanisms for chemotherapy-induced cognitive changes. Nature Reviews. Cancer 7, 192-201.
2. Ahles T.A., Saykin A.J., Furstenberg C.T., Cole B., Mott L.A., Skalla K., Whedon M.B., Bivens S., Mitchell T., Greenberg E.R. & Silberfarb P.M. (2002) Neuropsychological impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. Journal of Clinical Oncology 20, 485-493.
3. Ahles T.A., Saykin A.J., Mc Donald B.C., Furstenberg C.T., Cole B.F., Hanscom B.S., Mulrooney T.J., Schwartz G.N. & Kaufman P.A. (2007) Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Research and Treatment 110, 143-152.
4. Anderson-Hanley C., Sherman M.L., Riggs R., Agocha B. & Compas B.E. (2003) Neuropsychological impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. Journal of Clinical Oncology 20, 485-493.
5. Barden N. (2004) Implication of the hypothalamic-pituitary-adrenal axis in the physiopathology of depression. Journal of Psychiatry and Neuroscience 29, 185-193.
6. Bender C.M., Sereika S.M., Berga S.L., Vogel V.G., Brufsky A.M., Paraska K.K. & Ryan C.M. (2006) Cognitive impairment associated with adjuvant therapy in breast cancer. Psycho-Oncology 15, 422-430.
7. De Jong N., Candel M.J.J.M., Schouten H.C., Huijer Abu-Saad H. & Courtens A.M. (2005) Course of mental fatigue and motivation in breast cancer patients receiving adjuvant chemotherapy. Annals of Oncology 16, 372-382.
8. Earnheart J.C., Schweizer C., Crestani F., Iwasato T., Itohara S., Mohler H. & Lüscher B. (2007) GABAergic control of adult hippocampal neurogenesis in relation to behavior indicative of trait anxiety and depression states. The Journal of Neuroscience 27, 3845-3854.
9. Falleti M.G., Sanfilippo A., Maruff P., Weih L.A. & Phillips K.A. (2005) The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain and Cognition 59, 60-70.
10. Fayers P., Aaronson N., Bjordal K., Curran D. & Groenvold M. (1999) EORTC QLQ-C30 Scoring Manual, 2nd edn: EORTC Quality of Life Study Group. Emap Publisher, London, UK.
11. Folstein M.F., Folstein S.E. & McHugh P.R. (1975) 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. Psychiatry Research 12, 189-198.
12. Grassi L., Buda P., Cavana L., Annunziata M.A., Torta R. & Varetto A. (2005) Styles of coping with cancer: the Italian version of the Mini-Mental Adjustment to Cancer (Mini-MAC) scale. Psycho-Oncology 14, 115-124.
13. Hashimoto K., Shimizu E. & Iyo M. (2004) Critical role of brain-derived neurotrophic factor in mood disorders. Brain Research. Brain Research Reviews 45, 104-114.
14. Hermelink K., Untch M., Lux M.P., Kreienberg R., Beck T., Bauerfeind I. & Münzel K. (2007) Cognitive function during neoadjuvant chemotherapy for breast cancer. Cancer 109, 1905-1913.
15. Hermelink K., Kuchenhoff H., Untch M., Bauerfeind I., Lux M.P., Buhner M., Manitz J., Fensterer V. & Münzel K. (2010) Two different sides of 'chemobrain': determinants and nondeterminants of self-perceived cognitive dysfunction in a prospective, randomized, multicenter study. Psycho-Oncology 19, 1321-1328.
16. Hurria A., Somlo G. & Ahles T. (2007) Renaming 'chemobrain'. Cancer Investigation 25, 373-377.
17. Jansen E., Miaskoswski C., Dodd M., Dowling G. & Kramer J. (2005) A meta-analysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer 104, 2222-2233.
18. Jenkins V., Shilling V., Deutsch G., Bloomfield D., Morris R., Allan S., Bishop H., Hodson N., Mitra S., Sadler G., Shah E., Stein R., Whitehead S. & Winstanley J. (2006) A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. British Journal of Cancer 94, 828-834.
19. Karnofsky D.A., Abelmann W.H., Craver F. & Burchenal J.K. (1948) The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1, 634-656.
20. Meeter M., Talamini L., Schmitt J.A.J. & Rieder W.J. (2006) Effect of 5-HT on memory and the hippocampus: model and data. Neuropsychopharmacology 31, 712-720.
21. Montgomery S.A. & Asberg M. (1979) A new depression scale designed to be sensitive to change. The British Journal of Psychiatry 134, 382-389.
22. Pardo J.V., Pardo P.J., Humes S.W. & Posner M.I. (2006) Neurocognitive dysfunction in antidepressant-free, non-elderly patients with unipolar depression: alerting and covert orienting of visuospatial attention. Journal of Affective Disorders 92, 71-78.
23. Pullens M.J.J., De Vries J. & Roukema J.A. (2010) Subjective cognitive dysfunction in breast cancer patients: a systematic review. Psycho-Oncology 19, 1127-1138.
24. Raffa R., Duong P., Finney J., Garber D., Lam L., Mathew S., Patel N.N., Plaskett K.C., Shah M. & Jen Weng H.F. (2006) Is 'chemo-fog'/'chemo-brain' caused by cancer chemotherapy? Journal of Clinical Pharmacy and Therapeutics 31, 129-138.
25. Raven J.C. (1938) Standard Progressive Matrices: Sets A, B, C and D. HK Lewis, London, UK.
26. Reitan R.M. (1958) Validity of the Trail Making Test as an indication of organic brain damage. Perceptual and Motor Skills 8, 271-276.
27. Sartori G., Colombo L., Villar G., Rusconi M.L. & Pinarello A. (1997) T.I.B. Test di intelligenza breve per la valutazione del quoziente intellettivo attuale e pre-morboso. La Professione di Psicologo. Giornale dell'Ordine degli Psicologi 4 (1 Suppl. 6), 1-24.
28. Schagen S.B., van Dam F.S., Muller M.J., Boogerd W., Lindeboom J. & Bruning P.F. (1999) Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 85, 640-650.
29. Schagen S.B., Muller M.J., Boogerd W., Mellenbergh G.J. & van Dam F.S. (2006) Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. Journal of the National Cancer Institute 98, 1742-1745.
30. Schiepers O.J., Wichers M.C. & Maes M. (2005) Cytokines and major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 29, 201-217.
31. Shilling V. & Jenkins V. (2007) Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. European Journal of Oncology Nursing 11, 6-15.
32. Spinnler M. & Tognoni R. (1989) Standardizzazione e Taratura Italiana di Test Neuropsicologici. Italian Journal of Neurological Sciences 6 (Suppl. 8), 47-50.
33. Stewart A., Bielajew C., Collins B., Parkinson M. & Tomiak E. (2006) A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. The Clinical Neuropsychologist 20, 76-89.
34. Stewart A., Collins B., Mackenzie J., Tomiak E., Verma S. & Bielajew C. (2008) The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. Psycho-Oncology 17, 122-130.
35. Torta R. (2006) Depression as systemic disease: the antidepressant spectrum of action. Psycho-Oncology 15, 2-3.
36. Valentine A.D. & Meyers C.A. (2001) Cognitive and mood disturbance as causes and symptoms of fatigue in cancer patients. Cancer 92, 1694-1698.
37. Van Dam F.S., Schagen S.B., Muller M.J., Boogerd W., vd Wall E., Droogleever Fortuyn M.E. & Rodenhuis S. (1998) Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard dose chemotherapy. Journal of the National Cancer Institute 90, 210-218.
38. Vardy J., Rourke S. & Tannock I.F. (2007) Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. Journal of Clinical Oncology 25, 2455-2463.
39. Wagner L.I., Lai J.S., Cella D., Sweet J. & Forrestal S. (2004) Chemotherapy-related cognitive deficits: development of the FACT-Cog instrument. Annals of Behavioral Medicine 27, S10.
40. Wefel J.S., Lenzi R., Theriault R.L., Davis R.N. & Meyers C.A. (2004) The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100, 2292-2299.
41. Wefel J.S., Saleeba A.K., Buzdar A.U. & Meyers C.A. (2010) Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 116, 3348-3356.
42. Wieneke M.H. & Dienst E.R. (1995) Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology 4, 61-66.
43. Zigmond A.S. & Snaith R.P. (1983) The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica 67, 361-370.